Literature DB >> 24009163

Visual evoked potentials in neuromyelitis optica and its spectrum disorders.

Marius Ringelstein1, Ingo Kleiter, Ilya Ayzenberg, Nadja Borisow, Friedemann Paul, Klemens Ruprecht, Markus Kraemer, Eva Cohn, Brigitte Wildemann, Sven Jarius, Hans-Peter Hartung, Orhan Aktas, Philipp Albrecht.   

Abstract

Optic neuritis (ON) is a key feature of neuromyelitis optica (NMO). Recently, NMO patients of predominantly Afro-Brazilian origin were evaluated by visual evoked potentials (VEPs) and showed marked amplitude reductions. Here, we analyzed VEPs in a predominantly Caucasian cohort, consisting of 43 patients with definite NMO, 18 with anti-aquaporin (AQP) 4 antibody-seropositive NMO spectrum disorders and 61 matched healthy controls. We found reduced amplitudes in only 12.3%, prolonged latencies in 41.9% and a lack of response in 14.0% of NMO eyes. Delayed P100 latencies in eyes without prior ON suggested this was a subclinical affection. The data indicate heterogenous patterns in NMO, warranting further investigation.

Entities:  

Keywords:  Aquaporin-4 antibody; P100 latency; neuromyelitis optica; neuromyelitis optica spectrum disorders; optic neuritis; visual evoked potential

Mesh:

Substances:

Year:  2013        PMID: 24009163     DOI: 10.1177/1352458513503053

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  19 in total

1.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Authors:  Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

Review 2.  [Optical coherence tomography in neuromyelitis optica spectrum disorders].

Authors:  F C Oertel; H Zimmermann; A U Brandt; F Paul
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

Review 3.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 4.  Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.

Authors:  J L Bennett; J de Seze; M Lana-Peixoto; J Palace; A Waldman; S Schippling; S Tenembaum; B Banwell; B Greenberg; M Levy; K Fujihara; K H Chan; H J Kim; N Asgari; D K Sato; A Saiz; J Wuerfel; H Zimmermann; A Green; P Villoslada; F Paul
Journal:  Mult Scler       Date:  2015-02-06       Impact factor: 6.312

5.  Retinal Morphology and Sensitivity Are Primarily Impaired in Eyes with Neuromyelitis Optica Spectrum Disorder (NMOSD).

Authors:  Ryutaro Akiba; Hirotaka Yokouchi; Masahiro Mori; Toshiyuki Oshitari; Takayuki Baba; Setsu Sawai; Satoshi Kuwabara; Shuichi Yamamoto
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

6.  Optical Coherence Tomography versus Visual Evoked Potentials for Detecting Visual Pathway Abnormalities in Patients with Neuromyelitis Optica Spectrum Disorder.

Authors:  Nam Hee Kim; Ho Jin Kim; Cheol Yong Park; Kyoung Sook Jeong; Joong Yang Cho
Journal:  J Clin Neurol       Date:  2018-02-28       Impact factor: 3.077

Review 7.  Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.

Authors:  Frederike C Oertel; Hanna Zimmermann; Friedemann Paul; Alexander U Brandt
Journal:  EPMA J       Date:  2017-12-22       Impact factor: 6.543

Review 8.  Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

Authors:  Corinna Trebst; Sven Jarius; Achim Berthele; Friedemann Paul; Sven Schippling; Brigitte Wildemann; Nadja Borisow; Ingo Kleiter; Orhan Aktas; Tania Kümpfel
Journal:  J Neurol       Date:  2013-11-23       Impact factor: 4.849

9.  A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran.

Authors:  Davood Kashipazha; Seyed Ehsan Mohammadianinejad; Nastaran Majdinasab; Mostafa Azizi; Majid Jafari
Journal:  Iran J Neurol       Date:  2015-10-07

10.  Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.

Authors:  Orhan Aktas; Michael A Smith; William A Rees; Jeffrey L Bennett; Dewei She; Eliezer Katz; Bruce A C Cree
Journal:  Ann Neurol       Date:  2021-03-30       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.